ATLANTA, GA – – (Businesswire – August 4, 2020) – – Holzer & Holzer, LLC is investigating whether DBV Technologies S.A. (“DBV Technologies” or the “Company”) (NASDAQ: DBVT) complied with federal securities laws. On August 4, 2020, DBV Technologies announced it had received a CRL letter from the FDA outlining concerns regarding the efficacy and corresponding need for further testing of the Company’s BLA for Viaskin Peanut. The price of DBV Technology’s stock fell following the announcement. If you purchased shares of DBV Technology and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com or Luke R. Kennedy, Esq. at firstname.lastname@example.org, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.